Page 2568

Honda Clarity Fuel Cell Boasts EPA 366-Mile Range Rating, Best of Any Zero-Emission Vehicle

0
Honda Clarity Fuel Cell Boasts EPA 366-Mile Range Rating, Best of Any Zero-Emission Vehicle

TORRANCE, Calif., Oct. 24, 2016 /PRNewswire-HISPANIC PR WIRE/ — The Honda Clarity Fuel Cell sedan, launching later this year, received an EPA driving range rating of 366 miles and fuel economy rating of 68 miles per gallon of gasoline-equivalent combined1, giving it the best range rating of any electric vehicle without a combustion engine, including fuel cell and all-electric vehicles, in the United States.

Honda Clarity Fuel Cell Boasts EPA 366-Mile Range Rating, Best of Any Zero-Emission Vehicle

“Not only does the Clarity Fuel Cell fit five passengers and refuel in three to five minutes, it offers customers a driving range on par with gasoline-powered cars,” said Steve Center, vice president of the Environmental Business Development Office at American Honda Motor Co., Inc. “The Clarity leads the pack with a 366 mile driving range rating, and with a growing network of hydrogen stations and fast fueling time, the zero-emissions family road trip is no longer science fiction.”

Honda will introduce the new 5-passenger, hydrogen-powered Clarity Fuel Cell sedan by the end of 2016, beginning with retail leasing to customers through its expanded network of 12 approved fuel cell vehicle dealerships located in select California markets. The network includes six dealerships in Southern California, five in the Bay Area and one in Sacramento. Honda will further develop its dealer network as more hydrogen fueling stations become available.

Customers interested in the Clarity Fuel Cell are encouraged to visit http://automobiles.honda.com/clarity, where they can receive more information and sign up for the opportunity to become a Clarity Fuel Cell customer.

About the Honda Clarity Fuel Cell
Technological innovations to the Clarity Fuel Cell have created a fuel cell stack that is 33 percent more compact than its predecessor with a 60 percent increase in power density compared to the outgoing Honda FCX Clarity. The more compact fuel cell and integrated powertrain, comparable in size to a V-6 engine, now fits entirely under the hood of the car, allowing for a more spacious cabin with seating for five passengers. The Clarity Fuel Cell features a class-leading driving range rating for zero-emission vehicles with its EPA range rating of 366 miles, with a refueling time of approximately three to five minutes using 70 MPa refueling stations.

As the next progression in Honda’s dynamic FCV styling, the Honda Clarity Fuel Cell features a low, wide aerodynamic body with clean character lines. The interior achieves a refined and harmonious experience using rich materials and intuitive, streamlined controls. Additional features include the Honda Sensing™ suite of safety and driver assistive technologies, Apple CarPlay™ and Android Auto™ for smartphone connectivity, distinctive LED exterior lighting and 18-inch aluminum alloy wheels. The Clarity Fuel Cell will be available in Crystal Black Pearl, White Orchid Pearl and signature Bordeaux Red Metallic exterior paint schemes.

Honda Fuel Cell Vehicle Leadership
Honda has led the industry for nearly two decades in the development and deployment of fuel cell vehicle technology through extensive real-world testing and customer deployments, including the world’s first government fleet customers and first-ever retail consumer leasing program. Since the introduction of its first-generation fuel cell vehicle, the FCX, in 2002, Honda has made significant technological advancements in fuel cell vehicle operation in both hot and sub-freezing weather while meeting customer expectations and safety regulations.

Honda’s second-generation fuel cell vehicle, the FCX Clarity, launched in July 2008 and was quickly heralded as a technological breakthrough in the areas of design, packaging and efficiency. As the world’s first dedicated platform fuel cell vehicle, the FCX Clarity was powered by the smaller and lighter Honda V-flow fuel cell stack positioned in the center tunnel of the vehicle, with the smooth high torque front-wheel drive electric motor, providing performance on par with a gasoline powered sedan, including a 240 miles driving range rating.

Honda has deployed fuel cell vehicles in the U.S., Germany and Japan, including the FCX Clarity, which was named the 2009 World Green Car. Honda has delivered these vehicles to individual retail consumers in the U.S. and collected valuable feedback concerning real-world use of both fuel cell vehicles and public hydrogen refueling stations.

Honda Fuel Cell Vehicle Firsts
Honda fuel cell technology firsts include:

  • The first EPA- and CARB-certified fuel cell vehicle (July 2002)
  • The world’s first production fuel cell vehicle, introduced to the U.S. and Japan (December 2002)
  • The first fuel cell vehicle to start and operate in sub-freezing temperatures (2003)
  • The first fuel cell vehicle leased to an individual customer (July 2005)
  • The first manufacturer to build and produce a dedicated fuel cell vehicle (FCX Clarity) on a production line specifically made for fuel cell vehicles (2008)
  • The first manufacturer to create a fuel cell vehicle dealer network (2008)

Honda Commitment to the Environment
Based on its vision of “Blue Skies for our Children,” Honda is working to advance technologies that address society’s environmental and energy concerns. Honda is targeting a 50 percent reduction in its total company CO2 emissions on a global basis by 2050, compared to 2000 levels. Starting in 2016, Honda will begin introduction of a new generation of the Honda Clarity series of vehicles, with the hydrogen-powered Clarity Fuel Cell vehicle, followed by a new Clarity Electric and Clarity Plug-In Hybrid in 2017, as the company strives to realize significant growth in sales of electrified vehicles.

[1] 69 city / 67 highway / 68 combined miles per gallon of gasoline-equivalent (MPGe) rating; 366-mile driving range rating. Based on 2017 EPA ratings. Use for comparison purposes only. Your MPGe and driving range will vary based on how you drive and maintain your vehicle, driving conditions, powertrain condition, and other factors.

Honda Logo.

Photo – http://photos.prnewswire.com/prnh/20161024/431743
Logo – http://photos.prnewswire.com/prnh/20140415/73520LOGO

Fimbrion and GSK to Develop Novel Antibacterial Therapy for Urinary Tract Infections

0
Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO, founded in 2012 from intellectual property licensed from Washington University. Founders are Scott Hultgren, Ph.D., James Janetka, Ph.D., and Thomas Hooton, M.D. Fimbrion's mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. To learn more about Fimbrion technologies go to www.fimbrion.com.

ST. LOUIS, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — Fimbrion Therapeutics, Inc., a start-up biotechnology company focused on developing antibiotic-sparing drugs, has entered into collaboration with GlaxoSmithKline (GSK), a science-led global healthcare company, to develop a small molecule drug for the treatment and prevention of urinary tract infections (UTIs).

Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO, founded in 2012 from intellectual property licensed from Washington University. Founders are Scott Hultgren, Ph.D., James Janetka, Ph.D., and Thomas Hooton, M.D. Fimbrion's mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. To learn more about Fimbrion technologies go to www.fimbrion.com.

The agreement creates a joint project between Fimbrion and the Discovery Partnerships with Academia (DPAc) team at GSK. The project is focused on the preclinical development of a class of mannose-containing small molecule compounds called mannosides.  Mannosides may be able to treat and prevent urinary tract infections (UTIs) without inducing antibiotic resistance. Fimbrion founders Dr. Scott Hultgren, a microbiologist and expert in UTIs, and Dr. James Janetka, a medicinal chemist, combined efforts in 2009 to rationally design new classes of orally-bioavailable mannosides. Learn more about mannosides and other Fimbrion technologies at Fimbrion.com

Options for treating bacterial infections, especially those caused by Gram-negative bacteria, are becoming increasingly limited due to the exponential increase in antibiotic resistance.  Urinary tract infections are the third leading indication for antibiotic therapy and where multidrug-resistant bacteria are becoming increasingly common.

Mannosides represent a new way of treating bacterial infections, by simply preventing the bacteria from being able to stick to the walls of the bladder thus allowing the body to naturally eliminate the infection.

“We are excited for this strategic relationship and partnership with GSK enabling the development of our first drug candidate. This and other types of antibiotic-sparing therapeutics will be essential to prevent and treat increasingly prevalent infectious disease syndromes caused by antibiotic-resistant pathogens,” said Dr. Hultgren, President of Fimbrion Therapeutics.

“We are truly delighted to enter this collaboration to combine the disease expertise and mannoside discovery in Fimbrion with the drug discovery and development expertise of GSK for the development of a first-in-class therapeutic for the treatment of urinary tract infections,” said Carolyn Buser-Doepner, Global Head of Discovery Partnerships with Academia.  “Also exciting is that this is our group’s first collaboration with a start-up biotechnology company.”

Fimbrion’s initial focus is the development and commercialization of an orally active drug to prevent and treat urinary tract infections (UTIs). Fimbrion will continue to further develop its platform technology and pipeline with additional narrow-spectrum antimicrobial strategies to combat UTIs and other bacterial infections that can overcome existing mechanisms of resistance and minimize the emergence of new ones. These novel narrow-spectrum antimicrobial strategies being developed by Fimbrion could be effective novel therapies for multiple bacterial infections, while being minimally disruptive to the non-pathogenic, resident beneficial microbiota.

About Fimbrion Therapeutics, Inc.  Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO founded in 2012 from intellectual property licensed from Washington University. Founders are Scott Hultgren, Ph.D., James Janetka, Ph.D., and Thomas Hooton, M.D. Fimbrion’s mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. (www.fimbrion.com)

Fimbrion Contact:
Scott J. Hultgren, Ph.D.
Fimbrion Therapeutics, Inc.
4320 Forest Park Ave., Suite 304
St. Louis, MO 63108
[email protected]

Logo – http://photos.prnewswire.com/prnh/20161024/431990LOGO

American Urological Association and Sociedad Cubana de Urología Hold Inaugural Summit in Havana, Cuba

0
American Urological Association

LINTHICUM, Md., Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — The American Urological Association (AUA) and Sociedad Cubana de Urología (SCU) have partnered to present the inaugural AUA/SCU Summit to be held October 26-27 at El Palacio de Convenciones in Havana, Cuba.

American Urological Association

Manoj Monga, MD, AUA Secretary, as well as John Davis, MD and Rafael Gosalbez, MD will serve as AUA faculty and present the latest advances and treatments in urologic medicine in the areas of Endourology, Oncology and Pediatric Urology. Local experts will also present on the current state of urologic diseases and treatments in Cuba. Local hospital tours will serve as an opportunity for visiting urologists to gain further insight into the practice of urology in Cuba.

“There is a universal connection within the urologic community,” said Dr. Monga. “The AUA and Sociedad Cubana de Urología are committed to promoting the interchange of urological skills, education and patient care that is critical to the continued success of urology in the world community.”

In November 2015, leaders from the AUA and SCU signed a Memorandum of Understanding solidifying an educational bridge between the two organizations that includes joint educational programming with the goal to further cultivate the two parties’ friendship and collaboration and foster academic exchange among urologists within both associations.

“We are looking forward to this historic visit,” said Dr. Octavio Manuel de la Concepcion Gomez. “The AUA and Sociedad Cubana de Urología have been working toward this day for nearly a decade and are committed to providing quality education through this ground-breaking program in Havana, Cuba.”

The AUA has a long history with Cuba, with the Southeastern Section of the AUA actually having held its Annual Meeting in Havana more than 60 years ago. Now, the AUA looks to begin a new chapter of friendship and collaborations among the AUA and Cuban urology.

The AUA/SCU Summit was made possible through the generous support of KARL STORZ Endoskope.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 22,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Contact:

Christine Frey, AUA
443-909-0839, [email protected]

Logo – http://photos.prnewswire.com/prnh/20160210/332064LOGO

 

InComm Announces New Brand for Cash-In Solution, VanillaDirect™

0
InComm logo.

ATLANTA, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — InComm, a leading prepaid product and transaction services company, today announced the creation of a new brand of solutions for cash-based consumers, VanillaDirect. This new brand, which is the consolidation of the Cashtie and Vanilla Reload brands, will empower consumers to use cash to reload general-purpose reloadable (GPR) cards and to pay bills with cash at retailers nationwide, positioning InComm as an industry leader in digitizing cash at retail.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/7717651-incomm-introduces-vanilladirect

VanillaDirect will feature two innovative services at launch with more to be added in the future:

  • Load It Here allows cash-based consumers to easily and securely digitize their cash to load a wide variety of GPR cards. Load It Here utilizes InComm’s point-of-sale swipe reload technology to make reload experiences easier, faster and safer.
  • Pay It Here empowers cash-based consumers to pay bills for thousands of service providers in cash with a barcode at many retail locations nationwide. Consumers can download a barcode at PayItHere.com or present the barcode on their paper bill to a participating retail location.

“VanillaDirect fulfills InComm’s commitment to retailers and consumers with new and innovative payment solutions,” said Phil Graves, President, InComm. “The ability to digitize cash at our retailers has evolved beyond simple general-purpose reloads. We are excited to continue to leverage our innovative technology and expand the options consumers have for making payments and loading prepaid accounts, which will provide access for tens of millions of consumers who use cash in their everyday lives.”  

Despite many technological advances in the payments industry, many consumers still rely heavily on cash. A study by the Federal Reserve Bank of San Francisco found that 30 percent of American consumers prefer to use cash more frequently than any other payment instrument. With VanillaDirect, these consumers will have the added convenience of being able to pay participating billers and reload participating prepaid accounts at local retailers.

For more information, please contact an InComm representative or visit our website, VanillaDirect.com.

About InComm
Leveraging deep integrations into retailers’ point-of-sale systems, InComm provides connectivity to a variety of service providers that allow consumers to conduct everyday business at more than 500,000 points of retail distribution. Whether those consumers are activating prepaid products, paying bills, enjoying real-time discounts through a membership card, purchasing digital goods in-store or adding funds to an online account, InComm is there to provide unique gift-gifting opportunities, cater to on-the-go shoppers, deliver added value through loyalty programs and serve cash-based consumers. With 206 global patents, InComm is headquartered in Atlanta with a presence in 31 countries. Learn more at www.incomm.com or connect with us on www.twitter.com/incomm, www.facebook.com/incomm, www.linkedin.com/company/incomm or www.incomm.com/blog.

InComm logo.

Logo – http://photos.prnewswire.com/prnh/20110525/CL09221LOGO

Dos Equis Reveals More Legendary Adventures in First Commercial of The New Most Interesting Man in the World

0
Dos Equis Reveals More Legendary Adventures in First Commercial of The New Most Interesting Man in the World

WHITE PLAINS, New York, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — After premiering a trailer of The Most Interesting Man in the World last month, Dos Equis released a full-length commercial today, “Airboat“, revealing more of the character’s mystique and depth. In this latest installment, viewers ride full throttle alongside The Most Interesting Man and discover more about his legend, as he races airboats down sand dunes and spars in Samurai armor. The modernized campaign features a more interactive character whose adventures show why he’s different and how he’s gained his legendary status. The commercial also portrays how the creative and character have evolved over the past decade, reflecting the differences of what it means to be interesting to today’s millennial beer drinkers 21 and older.

Dos Equis Reveals More Legendary Adventures in First Commercial of The New Most Interesting Man in the World

“While ‘Legend Lines’ continue to be the backbone of our campaign, a lot has changed with the rollout of the evolved character,” said Andrew Katz, VP of Marketing for Dos Equis. “The Most Interesting Man is edgier and we’ve also modified the ‘Stay Thirsty, My Friends’ tagline at the end of each commercial. Staying true to the innate brand DNA, The Most Interesting Man can be seen celebrating interesting experiences with his amigos, while enjoying our new Dos Equis cans in high-energy settings.”

The creative evolution of the campaign, created by Havas Worldwide, is deeply rooted in research that the meaning of interesting has changed over the past decade: 84% of men think that what is interesting today is different from what was interesting a decade ago.1

“The new Most Interesting Man is a man of action. He’s never one to reminisce on times past, which stylistically changes everything. With a faster pace and more energy, we’re reinvigorating and modernizing one of the greatest campaigns,” said Toygar Bazarkaya, Chief Creative Officer of the Americas at Havas. “In the first full commercial, viewers will also see the Most Interesting Man being joined by an adventurous female travel companion who goes head-to-head with him.”

Synced with Dos Equis’ College Football Playoff sponsorship, The Most Interesting Man can also be seen giving a nod to the sport, and will be featured in two additional football-themed commercials running from the Playoff through the College Football Playoff National Championship on January 9, 2017. The 15-second spots, launching November 14, feature the icon at his helicopter RV tailgate in the Serengeti, kicking a field goal with a coconut through “the uprights” of two giraffes: “He has home field advantage, even when he’s away.”

The introduction of the evolved Most Interesting Man, the sponsorship of the College Football Playoff, and the rollout of the new logo, cans and packaging that hit shelves in the summer, are all efforts from Dos Equis to give fans the opportunity to embrace the Stay Thirsty mindset and elevate their drinking experience with the refreshing cerveza. For more information on the new Most Interesting Man, visit www.MostInterestingMan.com, or visit www.DosEquis.com and www.Facebook.com/DosEquis for more information on the brand.

About HEINEKEN USA
HEINEKEN USA Inc., the nation’s leading upscale beer importer, is a subsidiary of HEINEKEN NV, the world’s most international brewer. Core brands imported into the U.S. are Heineken®, the world’s most international premium beer brand, the Dos Equis franchise, the Tecate franchise and Strongbow Hard Apple Ciders. HEINEKEN USA also imports Amstel Light, Newcastle Brown Ale, Red Stripe, Sol, Indio, Carta Blanca and Bohemia brands. For the latest information on our company and brands, follow us on Twitter @HeinekenUSACorp, or visit HEINEKENUSA.com.

Media Contacts:
Dave Brigandi
Edelman Public Relations
[email protected] 
(212) 704-8177

Dayna Adelman
HEINEKEN USA
[email protected] 
(646) 341-3377

1 Dos Equis Study conducted by Edelman Intelligence, February 2016

Dos Equis Logo

Photo – http://photos.prnewswire.com/prnh/20161024/431956  
Logo – http://photos.prnewswire.com/prnh/20160408/353340LOGO

Sensis Wins Big at the 2016 ANA Multicultural Excellence Awards with its “Can I Bring It?” USDA Radio Ads

0

LOS ANGELES, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — Sensis was honored at this year’s ANA Multicultural Excellence Awards, where the cross-cultural marketing agency walked away with the Audio award for the radio spots it produced for USDA’s Animal and Plant Health Inspection Service (APHIS) – the agency responsible for protecting U.S. agriculture from invasive pests and diseases.

USDA APHIS engaged Sensis to create a campaign that would help reduce the amount of prohibited food or plant items that are carried by travelers into the U.S. mainland, while increasing awareness of the threat of invasive species entering the U.S. from other countries.  Sensis met the challenge with “Can I Bring It?” – an integrated, cross-cultural advertising campaign that reached multiple targets with tailored, in-language communications in Spanish, Mandarin, and English.  Sensis created in-language video, audio, outdoor billboards, digital ads as well as an easy-to-navigate website to help travelers find out if the food and plant items they wished to bring were allowed.  The agency’s audio creative is what earned Sensis the ANA Multicultural Excellence Award.

“As an agency with cross-cultural marketing at its core, this is a meaningful win for us,” says Jose Villa, founder and president of Sensis.  “Reaching multiple audiences in-culture, while driving measurable behavior change is what we do well, so receiving this recognition from our industry peers at the ANA reinforces our core mission.”

This is the first ANA Multicultural Excellence Award win for Sensis.

About USDA APHIS: The Animal and Plant Health Inspection Service is a multi-faceted Agency with a broad mission area that includes protecting and promoting U.S. agricultural health, regulating genetically engineered organisms, administering the Animal Welfare Act and carrying out wildlife damage management activities. These efforts support the overall mission of USDA, which is to protect and promote food, agriculture, natural resources and related issues.

About Sensis: Sensis is a cross-cultural marketing agency driving behavior change.  Working beyond ethnic boxes, the agency creates useful, digitally relevant content to drive consumer action across cultures.  Along with its integrated advertising core, Sensis offerings include specialty practices SensisHealth, SensisChallenges and SensisCMO.  Agency clients include the FDA, Sempra Energy, AltaMed Health Services, Sony Pictures, UCLA Extension, CalOptima, United Healthcare, Union Bank, WorldRemit, Germania Insurance, the OC Fair, the CDC, the U.S. Air Force, Boston College, and the Army National Guard.  For more information, visit SensisAgency.com.

FOR MORE INFORMATION, CONTACT:
Felischa Marye
Sensis
[email protected]
213.341.0171, ext. 750

Accelerated Cure Project for Multiple Sclerosis Approved for a $250,000 Engagement Award by the Patient-Centered Outcomes Research Institute

0

WALTHAM, Massachusetts, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — A team led by the Accelerated Cure Project for Multiple Sclerosis (ACP) has been approved for a Eugene Washington PCORI Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) to support development of the Multiple Sclerosis (MS) Minority Research Engagement Partnership Network, a collaboration designed to identify and address disparities and increase participation by underrepresented communities in MS medical research.

ACP will partner with Feinstein Kean Healthcare, a strategic communications firm, to build a representative Partnership Network of stakeholders who together can identify barriers to participation in multiple sclerosis (MS) medical research by underrepresented communities and develop and test solutions to address and overcome those barriers. Hollie Schmidt, Vice President of Scientific Operations at ACP, will lead the engagement project.

Although MS has traditionally been thought of as a disease more prevalent among White populations, recent studies show that African Americans may have the highest risk for not only for MS, but for more aggressive forms of the disease. African Americans and Latinos are also less likely to receive health services and treatments. Minorities have lower representation rates in MS medical research.

“There is a tremendous need to involve minority communities in the design and development of research, and to engage researchers in increasing their representation in clinical studies,” said Robert McBurney, President and CEO of the Accelerated Cure Project for MS. “This award will allow ACP to grow vital minority engagement in our own patient-powered MS research network, iConquerMS™, and in numerous other MS research projects. We are pleased that PCORI has recognized the potential this program has to make important inroads in building minority participation, not only in MS research, but in all areas of medical research.”

Focusing primarily on African-American and Hispanic-American communities, the Partnership Network will develop a partnership structure, strategy, and toolkit to support a variety of outreach activities, based on the analysis of barriers conducted by the network and the resulting strategies that are developed by the network in the first two years. ACP intends to build upon gains made beyond the period of the contract and serve as a model for outreach in other disease areas as well.

“Community participation in identifying key issues and solutions is of paramount importance to meaningful and relevant research and to sustainable change,” said Monique LaRocque, M.P.H., Senior Vice President at Feinstein Kean Healthcare. “The Partnership Network will bring more patients, caregivers, clinicians, researchers, and other healthcare stakeholders into the multiple sclerosis research process to build a community that is better equipped to participate in patient-centered research. It will be an inclusive, comprehensive, and far-reaching program that leverages synergies with the iConquerMS™ initiative.”

“As a Black woman living with multiple sclerosis, I am ecstatic that PCORI is recognizing the Accelerated Cure Project’s MS efforts,” said Anita Williams, an iConquerMS™ member and patient advisor to the minority engagement project. “It is so important to understand the barriers preventing underrepresented groups from participating in MS research and I am excited that there will a dedicated network to help address disparities in MS.”

The project is part of a portfolio of projects approved for PCORI funding to help develop a skilled community of patients and other stakeholders from across the entire healthcare enterprise and to involve them meaningfully in every aspect of PCORI’s work.

“This project was selected for Engagement Award funding not only for its commitment to engaging patients and other stakeholders, but also for its potential to increase the usefulness and trustworthiness of the information we produce and facilitate its dissemination and uptake,” said Jean Slutsky, PCORI’s Chief Engagement and Dissemination Officer. “We believe the results of this project may have potential to improve outreach among different underrepresented populations and other disease states, and we look forward to following its progress and working with ACP to share the results.”

ACP’s project and the other projects approved for funding by the PCORI Engagement Award Program were selected through a highly competitive review process in which applications were assessed for their ability to meet PCORI’s engagement goals and objectives, as well as program criteria. For more information about PCORI’s funding to support engagement efforts, visit http://www.pcori.org/content/eugene-washington-pcori-engagement-awards/.

PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund comparative effectiveness research that will provide patients, their caregivers, and clinicians with the evidence needed to make better-informed health and healthcare decisions. PCORI is committed to seeking input from a broad range of stakeholders to guide its work.

About Accelerated Cure Project for MS
Accelerated Cure Project for MS (ACP) is a nonprofit organization whose mission is to accelerate research efforts to improve diagnosis, to optimize treatment and to cure MS. ACP believes that research is the only way to greatly improve the outlook for people with MS. The organization promotes scientific collaboration and accelerates research by rapidly and cost-effectively providing researchers with data and biospecimens they need to explore novel research ideas that can lead to better diagnoses, to new treatments and to cures for people with MS. Its resources have supported more than 100 research studies worldwide that have generated more than 1 trillion returned data points for collaborative data mining and disease modeling. To learn more about the focus, activities, and impact of ACP, please visit http://www.acceleratedcure.org.

About Feinstein Kean Healthcare
Feinstein Kean Healthcare (FKH) is a leading strategy and communications partner for emerging and established organizations whose innovations are helping to transform life sciences and healthcare. The firm works with clients at the intersection where disruptive technologies and ideas influence medicine, clinical research and practice, business models, public policy, and public opinion and behaviors. For 25 years, FKH has been a trusted partner to leading pharmaceutical, healthcare, technology, biotechnology, informatics, and patient advocacy organizations. Hundreds of clients have turned to FKH to develop and execute programs that drive product commercialization; forge partnerships; transform markets; build constituencies; and help to shape policies. FKH established the first personalized medicine practice in the nation in 2004, and has worked with commercial, academic, and government innovators to advance adoption of personalized medicine approaches ever since. Learn more at http://fkhealth.com/.

About PCORI
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers, and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work. PCORI has awarded a total of $464.4 million since it began funding CER in 2012. For more information about PCORI funding, visit http://pcori.org/funding-opportunities. More information is available at www.pcori.org.

Contact:
Sara Loud
+1-781-487-0032
[email protected]

Latest FareCompare.com Analysis Reveals U.S. Cities Where Flyers Are Paying Less, More for Thanksgiving Airfare this Year

0

DALLAS, Oct. 25, 2016 /PRNewswire-HISPANIC PR WIRE/ — FareCompare.com has released new year-over-year Thanksgiving pricing comparisons from proprietary data based on the analysis of 3.2 million airfares for 25 of the busiest domestic markets. Highlights include:

  • Seventeen of the top 25 cities experienced a price decrease from 2016 to 2015
  • The cities with the biggest price drops for Thanksgiving airfare were:
    • Minneapolis/St. Paul: 15% less ($480 in 2016 vs $565 in 2015)
    • Cleveland: 10% less ($474 in 2016 vs. $526 in 2015)
    • Chicago: 9% less ($491 in 2016 vs. $540 in 2015)
    • Boston: 9% less ($615 in 2016 vs. $673 in 2015)
    • Indianapolis: 8% less ($462 in 2016 vs. $536 in 2015
  • The cities with the biggest price increases for Thanksgiving were:
    • Philadelphia: 11% more ($592 in 2016 vs. $575 in 2015)
    • Houston: 6% more ($575 in 2016 vs. $544 in 2015)
  • Orlando and Washington, D.C. saw no significant change

“Overall, this is good news for flyers in the U.S.,” said Rick Seaney, CEO and Co-Founder, FareCompare. “And it reinforces the notion that the four largest carriers in the U.S. continue to face stiff competition from a host of low cost carriers.”

The chart below breaks down the 25 cities included in the FareCompare Thanksgiving analysis. Fares were to domestic destinations and limited to nonstop and one-stop flights with a 60-90 advance purchase window departing the Tuesday or Wednesday before Thanksgiving and returning Saturday or Sunday.

City

2016

Average

Price

2015

Average

Price

Price

Change in $

 

Price

Change in %

 

Atlanta

$439

$453

($14)

-3%

Boston

$615

$673

($58)

-9%

Baltimore

$539

$531

$7

+1%

Chicago

$491

$540

($48)

-9%

Cleveland

$475

$527

($52)

-10%

Charlotte

$490

$499

($9)

-2%

Denver

$530

$535

($5)

-1%

Dallas/Fort- Worth

$518

$497

$21

+4%

Detroit

$505

$521

($16)

-3%

Houston

$575

$544

$32

+6%

Indianapolis

$492

$536

($44)

-8%

Las Vegas

$487

$474

$13

+3%

Los Angeles

$644

$621

$23

+4%

Miami

$443

$427

$16

+4%

Minneapolis/St. Paul

$480

$565

($85)

-15%

New York

$586

$624

($38)

-6%

Orlando

$431

$430

$1

0%

Portland

$593

$613

($20)

-3%

Philadelphia

$592

$535

$57

+11%

Phoenix

$499

$508

($10)

-2%

San Diego

$615

$621

($7)

-1%

San Antonio

$517

$530

($14)

-3%

Seattle

$600

$614

($14)

-2%

San Francisco

$668

$688

($20)

-3%

Washington, D.C.

$541

$543

($2)

0%

About FareCompare

Headquartered in Dallas, FareCompare makes shopping for airfare easy and simple by comparing currently available fares from a wide variety of sources through one simple search.  The company’s multiple products allow customers across the world to keep track of their favorite destinations and specific travel dates, plus find great low price deals that are not publicized through its best-in-class deal detection algorithms. FareCompare.com is the trusted source of 6 million global users every month.

Live Nation Entertainment Schedules Third Quarter 2016 Earnings Release And Teleconference

0

LOS ANGELES, Oct. 24, 2016 /PRNewswire-HISPANIC PR WIRE/ — Live Nation Entertainment, Inc. (NYSE: LYV), the world’s leading live entertainment and ecommerce company, announced today that it will release its third quarter 2016 financial results after market hours on Monday, November 7, 2016.  Michael Rapino, Live Nation Entertainment’s President and Chief Executive Officer, will host a teleconference that day to discuss the company’s financial performance at 5:00 p.m. ET.

The teleconference will be available via live webcast.  All interested parties should visit the “Events & Webcasts” section of the company’s website at www.investors.livenationentertainment.com to register for the webcast.  Supplemental statistical and financial information to be provided on the call, if any, will be available under the same link.

Additionally, Mr. Rapino will be making a presentation during the Liberty Media Corporation annual Investor Meeting at approximately 9:50 a.m. ET (6:50 a.m. PT) on Thursday, November 10, 2016 in New York City.  During his presentation, Mr. Rapino may address the company’s long-term strategic direction, financial performance, and outlook.

A live audio webcast of the conference presentation, as well as any accompanying written materials, will be available on the “Events & Webcasts” section of the company’s website at www.investors.livenationentertainment.com along with a replay of the webcast following the event.

About Live Nation Entertainment
Live Nation Entertainment (NYSE: LYV) is the world’s leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, Live Nation Media & Sponsorship and Artist Nation Management.  For additional information, visit www.livenationentertainment.com.